Skip to main content
Enrollment initiated for Phase I anti-BCMA CAR T-cell therapy trial

Cellular Biomedicine has begun to enroll patients in China for its Phase I clinical trial to assess the safety and efficacy of C-CAR088, its anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for patients with relapsed or refractory multiple myeloma.

Full Story: